Sponsored

Chimeric Therapeutics (ASX:CHM) appoints Dr McQualter as CEO amid advancing cancer trials

November 12, 2024 02:02 AM GMT | By Sonal Goyal
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 Chimeric Therapeutics (ASX:CHM) appoints Dr McQualter as CEO amid advancing cancer trials
Image source: Company PPT

Highlights

  • Chimeric Therapeutics has appointed Dr. Rebecca McQualter as CEO, effective immediately.
  • McQualter has extensive experience in regenerative medicine and cell therapy.
  • The company has three CAR T and NK cell assets in four Phase 1/1b clinical trials.

Chimeric Therapeutics Ltd. (ASX:CHM), a cancer cell therapy company, has appointed Dr. Rebecca McQualter, its Chief Operating Officer, as CEO, effective 12 November 2024.

Dr. McQualter holds extensive expertise specialising in regenerative medicine and cell therapy. She has held senior roles at international firms such as Novartis, Amgen, and GlaxoSmithKline. Throughout her career, she has demonstrated a proven ability to build commercial partnerships and strong networks with stakeholders across the healthcare and pharmaceutical industries.

Clinical Trial Progress

Currently, the company has three CAR T and NK cell assets in four Phase 1/1b clinical trials.

Image source: Company update

CHM CDH17, a first-in-class, 3rd generation CDH17 CAR T, received FDA IND clearance for its Phase 1/2 trial in 2023. This trial, initiated in 2024, is studying the therapy in gastrointestinal and neuroendocrine tumours. The dosing of the first patient has also been completed.

CHM CORE-NK is a clinically validated, off the shelf and enhanced natural killer (NK) cell platform. The acute myeloid leukemia (AML) patient achieved complete response in the CHM CORE-NK + Vactosertib Phase 1b clinical trial.

CHM CLTX, a novel CAR T therapy, is being studied in a phase 1B clinical trial for recurrent / progressive glioblastoma.

CHM shares were trading nearly 10% higher at AU$0.011 each at the time of writing on 12 November 2024.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

AI on the Rise: A Look at Top AI Companies and Their Stocks

Recent Articles

Investing Tips

Previous Next